Ozagrel sodium

• CAT Number: I001183
• CAS Number: 130952-46-4
• Molecular Formula: C13H11N2NaO2
• Molecular Weight: 250.23
• Purity: ≥95%
• Target: Thromboxane A2 Synthase
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: sodium;(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoate
• InChI: InChI=1S/C13H12N2O2.Na/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;/h1-8,10H,9H2,(H,16,17);/q;+1/p-1/b6-5+
• InChIKey: NCNYJCOBUTXCBR-IPZCTEOASA-M
• SMILES: C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)[O-].[Na+]

Ozagrel sodium（Cat No.:I001183）is a synthetic drug that acts as a selective thromboxane A2 (TXA2) receptor antagonist and inhibitor of thromboxane synthetase. It is primarily used as an antiplatelet agent to prevent platelet aggregation and reduce the risk of thrombotic events. Ozagrel sodium is commonly used in the management of acute ischemic stroke, myocardial infarction, and other conditions where blood clot formation plays a critical role. By inhibiting TXA2, ozagrel reduces vasoconstriction and platelet activation. Although effective, its use is typically monitored for potential side effects, including bleeding complications.

Reference

[1]. Nakazawa, M., et al., [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi, 1994. 114(12): p. 911-33.
[2]. Li, S.B., et al., In vitro effect of ozagrel on mushroom tyrosinase. Protein J, 2009. 28(3-4): p. 182-8.
[3]. Westphal, M., et al., Selective thromboxane A2 synthase inhibition by OKY-046 prevents cardiopulmonary dysfunction after ovine smoke inhalation injury. Anesthesiology, 2005. 102(5): p. 954-61.